Lingke Pharmaceuticals is authorized to develop new RAS inhibitors.

July 27 (UPI) -- Lingke Pharmaceuticals, a chinese innovative biopharmaceutical company, announced an exclusive licensing agreement with Kobe University of Japan and the Riken Research Institute of Japan to develop RAS inhibitors with a new drug action mechanism (MOA)At the same time, the agreement between Lingko Pharmaceuticals and Kobe University also includes continued technical support for active screening and structure seistating Kobe UniversityRAS are the main causes of many cancers, including pancreatic cancer (95%), colon cancer (50%) and lung adenocarcinoma (30%)RAS has been a target for the medical community since it was first discovered in the 1960s, but the results have been very limitedProgress has been made in recent years with irreversible binding inhibitors in the KRAS G12C mutation, but the therapy has not inhibited other, more common KRAS mutations, such as G12V and G12D"Lingko Pharmaceuticals will use its expertise in pharmaceutical chemistry and drug design to develop more ideal RAS inhibitors to target a wider range of 'non-drugable' RAS-induced malignancies and ultimately to develop clinically effective drugs based on the results of early structural biology and screening at Kobe University and RIKEN," said DrWan Zhaokui, founder, chairman and CEO of Lingko PharmaceuticalsFor us, this is an ambitious drug development process, and we challenge a target that has been 'non-drugable' for decades, but we believe that by working with two world-renowned research institutions to develop new targeted drugs using new drug mechanisms, we will certainly offer greater hope to cancer patientsLingco Pharmaceuticals is a clinical phase company dedicated to the discovery and development of new drugs for the treatment of cancer as well as immune and inflammatory diseasesFounded in March 2018, Lingco Pharmaceuticals is a global pharmaceutical company with experience in the field of drug discovery by experienced drug discovery expertsThe company's angel round financing by Kaitai Capital and Power Capital co-led the investment, National Pharmaceutical Capital and investmentIt is worth mentioning that lingcopharmaceuticals in the first half of 2020 ushered in two milestones of progressIn January, the company successfully completed tens of millions of until round of A financing, led by Decheng Capital, Zhejiang Merchants Innovation and former investors Power Capital and Kaitai Capital, and in April, the company successfully completed an overseas licensing license for preclinical candidate compounds, with down payments and milestone payments of nearly $200 million and a double-digit (percentage) potential sales increaseReference: Japan Institute of Science and Research and Kobe University authorize Lingko Pharmaceuticals to develop new RAS inhibitors exclusivelyRetrieved Jul 27, 2020, from